Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Inks Japanese Distribution Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems said today that it has signed up Takeda Rika Kogyo to distribute its genome analysis platform to life sciences research customers in Japan.

The exclusive agreement gives Takeda rights to sell the SmartChip System, which WaferGen is currently commercializing along with its SmartChip Gene Expression Profiling Services through an early-access program.

The SmartChip System includes a 5,184-assay SmartChip, the SmartChip Cycler, and the SmartChip Nanodispenser or Multi-Sample Nanodispenser for studying candidate genes and microRNA panels for disease research.

WaferGen's gene expression profiling services are provided to universities, research hospitals, and drug and biotech companies from the firm's Fremont, Calif. headquarters.

"By improving biomarker identification and validation, we believe that the SmartChip System will make a significant difference by enabling scientists to more quickly and effectively understand disease at the molecular level in order to target therapies," Takeda Rika Kogyo President Takuto Takeda said in a statement.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.